celvapan
nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vaccines - prophylaxis of influenza caused by a(h1n1)v 2009 virus.celvapan should be used in accordance with official guidance.
pandemic influenza vaccine h5n1 baxter (whole virion, vero cell derived, inactivated) suspension for injection 0.5 ml dose
au pharma pty ltd - influenza virus haemagglutinin, quantity: 15 microgram/ml - injection, suspension - excipient ingredients: trometamol; water for injections; sodium chloride; polysorbate 80 - pandemic influenza vaccine h5n1 baxter is indicated for prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official recommendations.
pandemic influenza vaccine h5n1 baxter ag
resilience biomanufacturing ireland limited - influenza vaccine (whole virion, inactivated) containing antigen of: a/vietnam/1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.
pandemic influenza vaccine h5n1 baxter
pharmacy retailing (nz) ltd t/a healthcare logistics - influenza vaccine whole virion, vero cell derived, inactivated 7.5ug (a(h5n1) (a/vietnam/1203/2004)); - suspension for injection - 7.5 mcg/0.5ml - active: influenza vaccine whole virion, vero cell derived, inactivated 7.5ug (a(h5n1) (a/vietnam/1203/2004)) excipient: polysorbate 80 sodium chloride trometamol water for injection - prophylaxis of influenza in an officially declared pandemic situation. the vaccine may only be marketed or distributed in accordance with the directives contained in the current version of the new zealand influenza pandemic action plan.
vepacel
ology bioservices ireland ltd - influenza virus (whole virion, inactivated), containing antigen of: a/vietnam/1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - influenza vaccines - active immunisation against h5n1 subtype of influenza a virus. this indication is based on immunogenicity data from subjects from the age of 6 months onwards following administration of two doses of vaccine prepared with h5n1 subtype strains. vepacel should be used in accordance with official guidance.,
celvapan
baxter healthcare ltd - influenza virus type a haemagglutinin 7.5ug equivalent to a/california/07/2009 (h1n1); - suspension for injection - 7.5 mcg - active: influenza virus type a haemagglutinin 7.5ug equivalent to a/california/07/2009 (h1n1) excipient: polysorbate 80 sodium chloride trometamol water for injection - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.
influenza a- h1n1 2009 monovalent vaccine injection, suspension
novartis vaccines and diagnostics ltd - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) (unii: k9p8pva2ug) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) - unii:k9p8pva2ug) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for immunization of persons 4 years of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. influenza a (h1n1) 2009 monovalent vaccine should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (eggs or egg products), or to any component of influenza a (h1n1) 2009 monovalent vaccine, or who has had a life-threatening reaction to previous influenza vaccinations [see description (11)]. novartis’ influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluvirin) are manufactured by the same process. available information for fluvirin is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluvirin. it is also not known whether influenza a (h1n1) 2009 monovalent vaccine or fluvirin can cause fetal harm when administered to
zoonotic influenza vaccine seqirus
seqirus s.r.l. - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaccines - active immunisation against h5 subtype of influenza a virus
adjupanrix (previously pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals)
glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.
adjupanrix (previously pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals)
glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human, immunization, disease outbreaks - vaccines, - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.,